Watanabe S, Sugihara T, Takahashi M, Ata K, Kanzaki A, Yamada O, Yawata Y
Department of Medicine, Kawasaki Medical School.
Rinsho Ketsueki. 1994 Sep;35(9):895-7.
A 44-year-old woman with progressive systemic sclerosis (PSS) visited our clinic because of leukocytosis and thrombocytosis. She was diagnosed as having chronic myelogenous leukemia (CML) with PSS, and was treated with interferon-alpha 2b (IFN-alpha) after pretreatment of hydroxyurea as a cytoreduction. Complete hematological remission was obtained two months later, and four months later minimal cytogenetic response was achieved by IFN-alpha. Her PSS symptoms were also improved to some extent as judged by Rodnan's total skin score, maximal opening distance of oral cavity, and range of motion of wrists. Our results suggest that IFN-alpha is probably beneficial not only for CML itself but also for PSS, too.
一名44岁的进行性系统性硬化症（PSS）女性因白细胞增多和血小板增多前来我院就诊。她被诊断为患有慢性粒细胞白血病（CML）合并PSS，在使用羟基脲进行细胞减灭预处理后，接受了α-2b干扰素（IFN-α）治疗。两个月后获得了完全血液学缓解，四个月后通过IFN-α实现了微小细胞遗传学反应。根据罗德南皮肤总分、口腔最大开口距离和手腕活动范围判断，她的PSS症状也有一定程度的改善。我们的结果表明，IFN-α可能不仅对CML本身有益，对PSS也有益。
